Cellora Gu Clinic's MOU with MEDIPOST and what it means for patients

The quality of stem cell therapy is not in the injection itself but in the cells produced by harvesting, isolation and culture. A partnership with a company experienced in cell culture therefore touches what the patient actually receives.

MEDIPOST is a Korean company known for Cartistem, a cell-drug product for knee cartilage that has been through regulatory approval. A company like that working with a clinic implies auditable process standards as a precondition.

It is worth separating what an MOU is from what it is not: it is a cooperation framework, not a guarantee that the cells a patient receives are that company's product. Ask specifically which process produced the cells in your case and who performed it.

In parallel, the clinic says it uses functional-medicine results to time harvesting when the body is at its best, cultures cells to high purity, and banks surplus cells for future use — an approach that depends directly on culture technology.

If you are comparing clinics, ask whether cells are cultured, for how long, how quality and contamination are tested, and whether you receive a cell-quality report.

Overall, an MOU with a cell-drug developer is a positive signal about process seriousness, but it should not replace condition-specific evidence: you still need to weigh how much support exists for stem cell use in your particular condition.